Assessing disease response is a critical endpoint in cancer clinical trials. Standard response criteria have been established by international consensus for solid tumors and hematologic malignancies. When measuring solid tumor lesions, the Response Evaluation Criteria in Solid Tumors (RECIST) is typically used. RECIST defines and standardizes measuring the overall tumor disease burden during a course of therapy. With the increase in immunotherapy, the need to modify RECIST has evolved. When these criteria are not well understood or consistently followed during a trial, it can put the study endpoint(s) in jeopardy. This webinar will describe how to use RECIST and iRECIST as well as identifying common errors seen during monitoring activities.

Presented by:
Elizabeth Ness, MS, BSN, RN, CRN-BC™
Director, Office of Compliance and Education
Center for Cancer Research, NCI

Rose Ermete BSN, RN, OCN®, CRN-BC™, CCRP®
Senior Quality Assurance Nurse Auditor
SWOG Cancer Research Network